KPV vs Thymosin Beta-4 Fragment (TB4-Frag 17-23)
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
KPV
KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). Despite its small size — just three amino acids — it retains the anti-inflammatory core activity of its parent molecule without the melanogenic effects. It is one of the most researched peptides for gut inflammation, IBD, and intestinal permeability, with the ability to act locally in the gut when administered orally.
Full profileThymosin Beta-4 Fragment (TB4-Frag 17-23)
The heptapeptide fragment (amino acids 17–23) of full thymosin beta-4, sequence Ac-LKKTETQ. This sequence is the active actin-binding domain responsible for TB-500's tissue repair properties. Shorter molecular weight than TB-500 enables more targeted delivery while retaining identical mechanism of action on G-actin regulation and tissue repair signaling.
Full profile| KPV | Thymosin Beta-4 Fragment (TB4-Frag 17-23) | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Lys-Pro-Val, Alpha-MSH C-terminal tripeptide | TB4 fragment 17-23, TB-500 active peptide, LKKTETQ, thymosin beta-4 fragment, Ac-LKKTETQ |
| Evidence | Research-stage | Research-stage |
| Dosing range | 250mcg–1000mcg mcg, Once or twice daily | 250mcg–1mg mcg–mg, 2–3x weekly |
| Administration | Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal | Subcutaneous injection, Intramuscular injection |
| Key side effects | Generally well-tolerated, Mild injection site irritation, Transient headache (uncommon), No melanogenic effects (does not cause tanning unlike full α-MSH) | Injection site irritation, Mild fatigue (transient), Potential headache, Generally well-tolerated in research applications |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: KPV — Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal; Thymosin Beta-4 Fragment (TB4-Frag 17-23) — Subcutaneous injection, Intramuscular injection.
- Dosing units differ: KPV is dosed in mcg, Thymosin Beta-4 Fragment (TB4-Frag 17-23) in mcg–mg — they operate at different scales.
- Frequency: KPV is typically Once or twice daily; Thymosin Beta-4 Fragment (TB4-Frag 17-23) is 2–3x weekly.
- Research depth: this profile cites 3 sources for KPV vs 2 for Thymosin Beta-4 Fragment (TB4-Frag 17-23).
How each works
KPV
KPV exerts anti-inflammatory effects through melanocortin receptor-independent mechanisms as well as via MC1R and MC3R activation. It downregulates NF-κB, inhibits pro-inflammatory cytokines (TNF-α, IL-1β, IL-8), and reduces neutrophil infiltration in colonic tissue. Uniquely for a peptide, KPV is acid-stable enough to survive gastric transit and reach the intestinal mucosa intact, making oral delivery viable for gut-targeted applications — a significant advantage over most injectable-only peptides.
Thymosin Beta-4 Fragment (TB4-Frag 17-23)
The LKKTETQ sequence was identified in 1994 as the minimum active fragment of thymosin beta-4 responsible for its actin-sequestering and tissue repair activity. This heptapeptide competes with actin monomer binding proteins, promoting cell migration, angiogenesis, and wound healing. Studies confirm it recapitulates the key bioactivity of full TB4 in cell migration and collagen deposition assays.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.